View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
March 22, 2018

Boston Scientific to acquire NxThera for $406m

Boston Scientific has signed a definitive agreement to purchase US-based NxThera for an upfront payment of $306m, and up to another $100m in potential commercial milestone-based payments over the coming four years.

Boston Scientific has signed a definitive agreement to purchase US-based NxThera for an upfront payment of $306m, and up to another $100m in potential commercial milestone-based payments over the coming four years.

Currently, Boston Scientific holds a minority stake in NxThera that is estimated to lead to a net upfront of about $240m after closing and milestone payments of up to $85m.

The acquisition is set to add NxThera’s Rezūm system to Boston Scientific’s Urology and Pelvic Health portfolio of treatments for various urological and gynaecological disorders.

NxThera developed and commercialised this minimally invasive therapy in the US and Europe for the treatment of symptoms caused due to benign prostatic hyperplasia (BPH).

“The acquisition is set to add NxThera’s Rezūm system to Boston Scientific’s Urology and Pelvic Health portfolio of treatments for various urological and gynaecological disorders.”

In 2015, the US Food and Drug Administration approved the Rezūm system, which also obtained CE-Mark. Since then, the system has been used to treat more than 20,000 patients.

Boston Scientific Urology and Pelvic Health senior vice-president and president Dave Pierce said: “The Rezūm system is an innovative therapy for men with symptomatic BPH that helps patients with a minimally invasive approach while reducing the cost and unwanted side effects that comes with taking maintenance medications.

“When compared with other minimally invasive BPH therapies, patients treated with the Rezūm system spend less time in the doctor’s office and have longer lasting improvement in their symptoms.”

Subject to customary closing conditions, the firm expects to close the acquisition in the second quarter of this year.

After completion, the Rezūm system is expected to complement Boston Scientific’s range of laser therapy systems, including the Greenlight XPS Laser Therapy system and holmium platforms, for symptomatic BPH treatment.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU